Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Further Reading

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

11 Nov 2013
Findings demonstrate potential new therapeutic approach to treat fibrotic diseases

Findings demonstrate potential new therapeutic approach to treat fibrotic diseases

11 Nov 2013
GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

8 Nov 2013
GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

8 Nov 2013
Researchers on the way to find cure against African sleeping sickness

Researchers on the way to find cure against African sleeping sickness

6 Nov 2013
JDRF partners with Pfizer's CTI to support diabetes research

JDRF partners with Pfizer's CTI to support diabetes research

4 Nov 2013
Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

31 Oct 2013
Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

From Cellectricon 31 Oct 2013
STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

STSI receives $29M grant to support innovative research on genomics, wireless technology and bioinformatics

23 Oct 2013
Sanofi uses QUOSA's literature management tools to automate adverse event monitoring

Sanofi uses QUOSA's literature management tools to automate adverse event monitoring

22 Oct 2013
Astrazeneca, Evotec Launch Kidney Disease Collaboration

Astrazeneca, Evotec Launch Kidney Disease Collaboration

21 Oct 2013
Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

19 Oct 2013
Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

18 Oct 2013
Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

17 Oct 2013
Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

16 Oct 2013
New method may pave way to effective, targeted cancer treatments

New method may pave way to effective, targeted cancer treatments

16 Oct 2013
Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

From Xstrahl 15 Oct 2013
Researchers discover new approach to tackle global threat of antibiotic drug resistance

Researchers discover new approach to tackle global threat of antibiotic drug resistance

13 Oct 2013
Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

10 Oct 2013
Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

9 Oct 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback